Ki67 was validated as an informative endpoint in several breast cancer trials treating patients with a neoadjuvant aromatase inhibitor (AI) and/or tamoxifen, with predictive value for long-term adjuvant endocrine treatment response6–10. Here, MKI67 is linked to breast carcinoma.